Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
Vince Biemans(Radboud University Nijmegen), Mark Löwenberg(Amsterdam University Medical Centers), J Haans(Maastricht University Medical Centre), Bas Oldenburg(University Medical Center Utrecht), Nidhi Srivastava, Marieke Pierik(Maastricht University Medical Centre), Annemarie C. de Vries(Erasmus MC), Frank Hoentjen(Radboud University Nijmegen), Alexander Bodelier(Amphia Ziekenhuis), Andrea E. van der Meulen‐de Jong(Leiden University Medical Center), Gerard Dijkstra(University Medical Center Groningen), C. Janneke van der Woude(Radboud University Nijmegen), Dirk de Jong(University Medical Center Groningen), Rachel West(Sint Franciscus Gasthuis), Nanne K.H. de Boer, Jeroen M. Jansen(OLVG)
Cited by 129
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
|The Lancet|2015|779
Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial
|The Lancet Oncology|2011|470
Complex host genetics influence the microbiome in inflammatory bowel disease
|Genome Medicine|2014|431